Latest News

Tuesday, January 16, 2018 | Movement Disorders

Parkinson’s Advocates in Research Leadership Awards

November 29, 2017 -- The Parkinson's Foundation announced $60,000 in support of patient-scientist teams to develop innovations to engage patients in their care. These awards expand the Parkinson&#…

Read the full story

Wednesday, January 10, 2018 |

Parkinson’s Outcomes Project Enrolls 10,000th Patient and Releases Key Findings

The "Parkinson's Outcomes Project," launched in 2009 as a small pilot and funded by the Parkinson's Foundation, met a major milestone goal with the enrollment of its 10,000th pa…

Read the full story

Monday, January 08, 2018 | Clinical Trials, Headache & Pain, Phase 3/4 Trials

PROMISE Phase 3 Trial for Chronic Migraine Prevention Meets Primary and All Key Secondary Endpoints; Shows Reduction in Migraine Risk

January 8, 2018--Alder Biopharmaceutical reported that their injectable calcitonin-gene-related peptide (CGRP)-inhibitor eptinezumab, in phase 3 clinical trials, reduced monthly migraine days by 50% o…

Read the full story

Wednesday, November 29, 2017 |

Awards: Parkinson's Advocates in Research Leadership

November 29, 2017 -- The Parkinson's Foundation announced $60,000 in support of patient-scientist teams to develop innovations to engage patients in their care. These awards expand the Parkinson&#…

Read the full story

Tuesday, November 07, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Phase 3/4 Trials, Product Launches and Updates

Oral Vimpat Approved for Use in Pediatric Patients with Partial-Onset Seizures

The FDA approved a label extension for Vimpat (lacosamide, UCB) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients four years and older. The expanded ind…

Read the full story

Friday, October 27, 2017 | Clinical Trials, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Biogen

ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple sclerosis (MS) who had the disea…

Read the full story

Friday, October 27, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Merck & Co. H

ECTRIMS: EMD Serono Highlights Risk-Benefit Profile of Cladribine Tablets for Relapsing MS

Data from a post-hoc analysis presented by Merck at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris show that investigational Cladribine Tablets significantly increases the proportion of patients with …

Read the full story

Friday, October 27, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications

ECTRIMS: Alkermes Demontrates Safety and GI Tolerability of Investigational Oral Agent for Relapsing MS

Alkermes presented safety and gastrointestinal (GI) tolerability data from EVOLVE-MS-1, an ongoing open-label, two-year phase 3 safety study for ALKS 8700, a novel, oral monomethyl fumarate (MMF) prod…

Read the full story

Friday, October 27, 2017 | Healthcare Trends, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

ECTRIMS: Genentech Data Signals Emphasis on Multiple Sclerosis Disease Progression, Disability

Data presented by Genentech at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) -- Americas Committee for Treatment and Research in Multiple Sclerosis (ACT…

Read the full story

Tuesday, October 24, 2017 | Concussion & Brain Injury, Personnel/Company News

Neural Analytics Partners with Department of Defense to Develop Portable Device to Assess Combat-Related TBI

The Department of Defense (DoD) has awarded Neural Analytics, Inc. a $10 million contract to develop and supply a portable, point-of-injury device for assessing combat-related traumatic brain inj…

Read the full story

Tuesday, October 24, 2017 | Dementia & Cognitive Disorders, FDA Approval/Clearance, Phase 3/4 Trials, Research and Publications

FDA Fast-Tracks Alzheon’s Anti-Amyloid Alzheimer’s Agent

The FDA has granted Fast Track designation to Alzheon, Inc.’s investigational anti-amyloid drug ALZ-801 for the treatment of Alzheimer’s disease (AD). Using a precision medicine approach, …

Read the full story

Friday, October 20, 2017 | Multiple Sclerosis & Immune Disorders, Research and Publications

Corrona Partners with National MS Society on Registry to Assess Safety and Efficacy of Therapies

Corrona, LLC and the National Multiple Sclerosis Society will collaborate on the launch of the Corrona Multiple Sclerosis (MS) Registry to study the comparative safety and effectiveness of approved MS…

Read the full story

Thursday, October 19, 2017 | Product Launches and Updates, Research and Publications

Phenogenetic Database For Stem Cell Models of Neurological Diseases Launched

Based on the results of a novel meta-analysis of all induced pluripotent stem cells, researchers have created an atlas of how cell characteristic in neurological and neurodegenerative diseases are lin…

Read the full story

Wednesday, October 18, 2017 | Concussion & Brain Injury, Research and Publications

National Grant Awarded to Mount Sinai to Continue the New York Traumatic Brain Injury Model System

The National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR) has awarded the Icahn School of Medicine at Mount Sinai’s Department of Rehabilitation Medicine and…

Read the full story

Thursday, October 12, 2017 | FDA Approval/Clearance, Headache & Pain, Phase 3/4 Trials, Research and Publications, Pfizer

Once-Daily Lyrica Formulation Wins FDA Approval

The FDA has approved Lyrica CR (pregabalin, Pfizer) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and t…

Read the full story
Load More